These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 32881669)

  • 1. Darolutamide as a Second-Generation Androgen Receptor Inhibitor in the Treatment of Prostate Cancer.
    Abbasi A; Movahedpour A; Amiri A; Najaf MS; Mostafavi-Pour Z
    Curr Mol Med; 2021; 21(4):332-346. PubMed ID: 32881669
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Moving Towards Precision Urologic Oncology: Targeting Enzalutamide-resistant Prostate Cancer and Mutated Forms of the Androgen Receptor Using the Novel Inhibitor Darolutamide (ODM-201).
    Borgmann H; Lallous N; Ozistanbullu D; Beraldi E; Paul N; Dalal K; Fazli L; Haferkamp A; Lejeune P; Cherkasov A; Gleave ME
    Eur Urol; 2018 Jan; 73(1):4-8. PubMed ID: 28851578
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TAS3681, an androgen receptor antagonist, prevents drug resistance driven by aberrant androgen receptor signaling in prostate cancer.
    Yoshida S; Kajiwara D; Seki M; Tayama M; Tanaka Y; Mizutani H; Fujita R; Yamamura K; Okajima S; Asai M; Minamiguchi K
    Mol Oncol; 2024 Aug; 18(8):1980-2000. PubMed ID: 38600681
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Darolutamide (ODM-201) for the treatment of prostate cancer.
    Shore ND
    Expert Opin Pharmacother; 2017 Jun; 18(9):945-952. PubMed ID: 28490267
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Developing a Novel Enzalutamide-Resistant Prostate Cancer Model via AR F877L Mutation in LNCaP Cells.
    Wang R; Ma S; Xu N; Gan Y; Li P; Zhang J; Zhang Z; Gu Q; Xiang J
    Curr Protoc; 2024 Apr; 4(4):e1033. PubMed ID: 38652202
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Development of Darolutamide: A Novel Androgen Receptor Antagonist for the Treatment of Prostate Cancer.
    Fizazi K; Smith MR; Tombal B
    Clin Genitourin Cancer; 2018 Oct; 16(5):332-340. PubMed ID: 30197098
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Isolation and characterization of castration-resistant prostate cancer LNCaP95 clones.
    Leung JK; Tam T; Wang J; Sadar MD
    Hum Cell; 2021 Jan; 34(1):211-218. PubMed ID: 32954481
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination therapy with androgen receptor N-terminal domain antagonist EPI-7170 and enzalutamide yields synergistic activity in AR-V7-positive prostate cancer.
    Hirayama Y; Tam T; Jian K; Andersen RJ; Sadar MD
    Mol Oncol; 2020 Oct; 14(10):2455-2470. PubMed ID: 32734688
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Second-Generation Androgen Receptor Antagonists as Hormonal Therapeutics for Three Forms of Prostate Cancer.
    Rajaram P; Rivera A; Muthima K; Olveda N; Muchalski H; Chen QH
    Molecules; 2020 May; 25(10):. PubMed ID: 32456317
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Randomized, Open-label, Cross-over Phase 2 Trial of Darolutamide and Enzalutamide in Men with Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer: Patient Preference and Cognitive Function in ODENZA.
    Colomba E; Jonas SF; Eymard JC; Delva R; Brachet PE; Neuzillet Y; Penel N; Roubaud G; Bompas E; Mahammedi H; Longo R; Helissey C; Barthélemy P; Borchiellini D; Hasbini A; Priou F; Saldana C; Voog E; Narcisso B; Ladoire S; Berdah JF; Aisenfarb JB; Foulon S; Fizazi K
    Eur Urol; 2024 Mar; 85(3):274-282. PubMed ID: 37271630
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Hospitalization-Related Costs of Adverse Events for Novel Androgen Receptor Inhibitors in Non-Metastatic Castration-Resistant Prostate Cancer: An Indirect Comparison.
    Shore N; Jiang S; Garcia-Horton V; Terasawa E; Steffen D; Chin A; Ayyagari R; Partridge J; Waldeck AR
    Adv Ther; 2022 Nov; 39(11):5025-5042. PubMed ID: 36028656
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Continued androgen signalling inhibition improves cabazitaxel efficacy in prostate cancer.
    Mout L; van Royen ME; de Ridder C; Stuurman D; van de Geer WS; Marques R; Buck SAJ; French PJ; van de Werken HJG; Mathijssen RHJ; de Wit R; Lolkema MP; van Weerden WM
    EBioMedicine; 2021 Nov; 73():103681. PubMed ID: 34749299
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interleukin-23 Represses the Level of Cell Senescence Induced by the Androgen Receptor Antagonists Enzalutamide and Darolutamide in Castration-Resistant Prostate Cancer Cells.
    Gupta S; Pungsrinont T; Ženata O; Neubert L; Vrzal R; Baniahmad A
    Horm Cancer; 2020 Aug; 11(3-4):182-190. PubMed ID: 32562083
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination therapy with novel androgen receptor antagonists and statin for castration-resistant prostate cancer.
    Nakayama H; Sekine Y; Oka D; Miyazawa Y; Arai S; Koike H; Matsui H; Shibata Y; Suzuki K
    Prostate; 2022 Feb; 82(3):314-322. PubMed ID: 34843630
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Androgen receptor enhancer amplification in matched patient-derived xenografts of primary and castrate-resistant prostate cancer.
    Porter LH; Bakshi A; Pook D; Clark A; Clouston D; Kourambas J; ; Goode DL; Risbridger GP; Taylor RA; Lawrence MG
    J Pathol; 2021 Jun; 254(2):121-134. PubMed ID: 33620092
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting the androgen receptor signaling pathway in advanced prostate cancer.
    Chung C; Abboud K
    Am J Health Syst Pharm; 2022 Jul; 79(15):1224-1235. PubMed ID: 35390118
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of Cerebral Blood Flow in Regions Relevant to Cognition After Enzalutamide, Darolutamide, and Placebo in Healthy Volunteers: A Randomized Crossover Trial.
    Williams SCR; Mazibuko N; O'Daly O; Zurth C; Patrick F; Kappeler C; Kuss I; Cole PE
    Target Oncol; 2023 May; 18(3):403-413. PubMed ID: 37103658
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Androgen receptor antagonists produced by Streptomyces overcome resistance to enzalutamide.
    Imoto M; Fujimaki T; Saito S; Tashiro E
    J Antibiot (Tokyo); 2021 Oct; 74(10):706-716. PubMed ID: 34282313
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improvement in overall survival with Apalutamide, Darolutamide and Enzalutamide in patients with non-metastatic castration-resistant prostate cancer.
    Swami U; Agarwal N
    Cancer Treat Res Commun; 2020; 25():100205. PubMed ID: 32822968
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Steroid Sulfatase Stimulates Intracrine Androgen Synthesis and is a Therapeutic Target for Advanced Prostate Cancer.
    Armstrong CM; Liu C; Liu L; Yang JC; Lou W; Zhao R; Ning S; Lombard AP; Zhao J; D'Abronzo LS; Evans CP; Li PK; Gao AC
    Clin Cancer Res; 2020 Nov; 26(22):6064-6074. PubMed ID: 32928794
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.